Abstract
We examined pharmacokinetic-targeted IV busulfan (75–170 mg/m2, with target AUC of 3500–6000 μmol min) and fludarabine (40 mg/m2) × 4 days with rituximab (t-IV Bu/Flu + rituximab) 375 mg/m2 on days +1 and +8 followed by allogeneic hematopoietic cell transplantation in 19 patients (median age 56, range 35–68 years) with CD20+ lymphoid malignancies. Median time to neutrophil and platelet engraftment was 15 and 12 days. The cumulative incidence of grade II–IV acute graft-versus-host disease (GVHD) was 58% (95% confidence interval, CI 39–85%), and chronic GVHD was 50% (95% CI 28–88%). With a median follow up of 7 (range 1–31) months, overall response was observed in 15, and stable or progressive disease in 4. Overall survival at 1 year was 67%. Engraftment, chimerism, and infectious complications did not differ significantly from a contemporaneous non-rituximab containing comparator group. The addition of rituximab 375 mg/m2 to t-IV Bu/Flu does not appear to adversely affect engraftment, donor chimerism, or increase the risk of infectious complications.
Similar content being viewed by others
References
Kharfan-Dabaja MA, Anasetti C, Santos ES. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol Blood Marrow Transpl. 2007;13:373–85.
Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009;114:1469–76.
Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematol Am Soc Hematology Educ Program. 2006;390–7.
van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009;610–8.
Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007;233–42.
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359:613–26.
Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595–9.
Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530–6.
Glass B. Rituximab for graft-versus-host disease prophylaxis after allogeneic stem cell transplantation given as treatment of high risk relapse of aggressive lymphoma: results of a randomized phase II study. Blood. 2008;112:689–90.
Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2009;145:816–24.
Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transpl. 2003;9:505–11.
Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756–62.
Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transpl. 2009;15:1005–13.
de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–64.
Pidala J, Kim J, Anasetti C, et al. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transpl. [Epub ahead of print]; 2010.
Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.
Kharfan-Dabaja M, Tate C, Perkins J, Fernandez H, Field T, Ayala E, Perez L, Raychaudhuri J, Alsina M, Ochoa-Bayona L, Sullivan D, Brand L, Poling W, Anasetti C. Rituximab is feasible to administer to allograft recipients with advanced CD20+ malignancies and does not affect timely hematopoietic engraftment. Biol Blood Marrow Transpl. 2008;14:121–2.
Conflict of interest
The authors report the following funding sources which have relevance to the work described here: Claudio Anasetti, MD, and Janelle Perkins, PharmD, have research funding from Protein Design Labs BioPharma for the conduct of research involving busulfan and fludarabine as conditioning therapy prior to allogeneic transplantation.
Author information
Authors and Affiliations
Corresponding author
Additional information
J. Pidala and J. Roman-Diaz contributed equally to this work.
About this article
Cite this article
Pidala, J., Roman-Diaz, J., Kim, J. et al. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol 93, 206–212 (2011). https://doi.org/10.1007/s12185-010-0747-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-010-0747-x